Disclosed is the use of an EGFL8 antagonist in the manufacture of a medicament for reducing or inhibiting angiogenesis in a subject having a pathological condition associated with angiogenesis, wherein the EGFL8 antagonist is an antagonist antibody or antibody fragment, a fragment or amino acid sequence variant of a native EGLF8 polypeptide, an antisense RNA or DNA construct, an inhibitory duplex RNA, a ribozyme, a nucleic acid in triple-helix formation, or an RNAi.
